Skip to main content
. 2018 Dec 18;129(2):569–582. doi: 10.1172/JCI122367

Figure 5. FOXA1 protein levels are decreased, whereas pSMAD is increased in metastatic CRPC as compared with primary PC.

Figure 5

Immunohistochemistry staining was performed in TMA of primary prostate tumors and metastatic CRPC with indicated antibodies. (A and C) Representative images of FOXA1 (A) and pSMAD2 (C) staining in a primary tumor (top) and a CRPC tumor (bottom). Scale bars: 200 μm. (B and D) Quantification of FOXA1 (B) and pSMAD2 (D) staining intensities in primary PC and CRPC samples.

HHS Vulnerability Disclosure